I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
I-Mab Poised To Capitalize On Growing Oncology Sector, Needham Says In Bullish Initiation
Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ:IMAB) offer strong upside potential, according to a Needham analyst.
The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target.
The I-Mab Takeaways: I-Mab has an extensive pipeline of innovative assets, including several assets in clinical trials in the U.S. as well as in China, Messer said in a Monday note.
The company has struck four out-licensing partnerships worth up to $3 billion, the analyst said.
I-Mab has also expanded its Chinese business by in-licensing Chinese rights to late-stage assets from biopharma companies such as Ferring, MorphoSys AG (NASDAQ:MOR) and MacroGenics, Inc. (NASDAQ:MGNX), he said.
Related Link: The Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
I-Mab's lead asset lemzoparlimab, which targets CD47, differentiates itself from other CD47 antibodies by having minimal interaction with RBCs, Messer said.
It is being evaluated in Phase 1 studies as a single agent as well as combo therapy option, the analyst said.
I-Mab's in-licensed asset Felzartamab could mark I-Mab's entry into commercialization in China as early as this year, he said.
"We believe its deep pipeline of proprietary IO assets will allow I-Mab to capitalize on an important, growing sector of oncology."
The company's unique go-to-market strategy in China will likely turn it into a fully integrated Chinese pharmaceutical company with global development expertise, in Needham's view.
IMAB Price Action: At last check, the stock was adding 0.44% to $55.25.
Related Link: Roche Boosts Diagnostics Portfolio With $1.8B Bet On COVID-19 Test Manufacturer GenMark
Shares of the U.S.-listed Chinese immuno-oncology company I-Mab (NASDAQ:IMAB) offer strong upside potential, according to a Needham analyst.
这家在美国上市的中国免疫肿瘤学公司的股票I-Mab(纳斯达克：IMAB)提供了强大的上行潜力，根据Needham的一位分析师的说法。
The I-Mab Analyst: Chad Messer initiated coverage of I-Mab shares with a Buy rating and $75 price target.
I-Mab分析师：查德·梅塞尔发起了关于I-Mab股票评级为买入，目标价为75美元。
The I-Mab Takeaways: I-Mab has an extensive pipeline of innovative assets, including several assets in clinical trials in the U.S. as well as in China, Messer said in a Monday note.
I-Mab外卖：梅塞尔在周一的一份报告中说，i-Mab拥有广泛的创新资产渠道，包括在美国和中国进行临床试验的几项资产。
The company has struck four out-licensing partnerships worth up to $3 billion, the analyst said.
这位分析师说，该公司已经达成了四项对外许可合作伙伴关系，价值高达30亿美元。
I-Mab has also expanded its Chinese business by in-licensing Chinese rights to late-stage assets from biopharma companies such as Ferring, MorphoSys AG (NASDAQ:MOR) and MacroGenics, Inc. (NASDAQ:MGNX), he said.
Related Link: The Week Ahead In Biotech (March 14-20): Update On Fibrogen-AstraZeneca's Anemia Drug, Earnings and Presentations
I-Mab's lead asset lemzoparlimab, which targets CD47, differentiates itself from other CD47 antibodies by having minimal interaction with RBCs, Messer said.
梅塞尔说，I-Mab的主要资产Lemzoparlimab针对CD47，与其他CD47抗体的区别在于与红细胞的相互作用最小。
It is being evaluated in Phase 1 studies as a single agent as well as combo therapy option, the analyst said.
这位分析师说，它正在作为单一药物和联合治疗选择在第一阶段研究中进行评估。
I-Mab's in-licensed asset Felzartamab could mark I-Mab's entry into commercialization in China as early as this year, he said.
他说，i-Mab的授权资产Felzartamab可能标志着i-Mab最早于今年进入中国商业化。
"We believe its deep pipeline of proprietary IO assets will allow I-Mab to capitalize on an important, growing sector of oncology."
我们相信，其深厚的专有IO资产流水线将使i-Mab能够利用一个重要的、不断增长的肿瘤学部门。“
The company's unique go-to-market strategy in China will likely turn it into a fully integrated Chinese pharmaceutical company with global development expertise, in Needham's view.
在李约瑟看来，该公司在中国独特的入市战略可能会使其成为一家完全整合的具有全球开发专长的中国制药公司。
IMAB Price Action: At last check, the stock was adding 0.44% to $55.25.
IMAB价格操作：在最后一次检查中，该股上涨了0.44%，至55.25美元。
译文内容由第三方软件翻译。
风险及免责提示
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能，分享给你的好友吧